Lentiviral Vector Gene Therapy for ADA-SCID Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) such as allogeneic hematopoietic stem cell transplant and enzyme replacement therapy have limited effectiveness and safety concerns, including poor immune recovery, high costs, and risks of adverse immune responses and insertional mutagenesis with gamma-retroviral vectors.
Innovation Solution
Development of self-inactivating HIV-1 lentiviral vectors with the EFS promoter for systemic delivery of the ADA gene to hematopoietic stem cells, which reduces the risk of insertional mutagenesis and achieves improved immune and metabolic recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gamma-retroviral vectors are used for gene therapy, then gene delivery is achieved, but insertional mutagenesis and adverse immune responses occur
Solution Approach 1:
The patent divides the retroviral vector into two separate vectors: a first vector delivering the ADA gene without strong LTR enhancer elements, and a second vector delivering the selectable marker gene. This segmentation eliminates the insertional mutagenesis risk from the ADA gene delivery while maintaining gene transfer effectiveness through the combined action of both vectors.
Solution Approach 2:
The patent introduces a selectable marker gene as an intermediary element delivered by a separate vector. This marker serves as a mediator to identify and select successfully transduced cells without the marker itself causing insertional mutagenesis, thus resolving the contradiction between effective gene delivery and safety.
2Reliability
If allogeneic hematopoietic stem cell transplant is performed, then immune recovery is attempted, but graft versus host disease and poor survival occur
Solution Approach 1:
The patent uses the patient's own hematopoietic stem cells (autologous transplantation) that have been genetically modified ex vivo to express the ADA gene. These self-service cells avoid the immunological incompatibility and graft versus host disease associated with allogeneic transplants, while providing sustained immune recovery through endogenous ADA production.
3Reliability
If enzyme replacement therapy with PEG-ADA is administered, then metabolic detoxification is achieved, but long-term immune recovery remains suboptimal and costs are extremely high
Solution Approach 1:
The patent performs preliminary genetic modification of hematopoietic stem cells ex vivo to establish endogenous ADA production capability before transplantation. This preliminary action creates a self-sustaining system that eliminates the need for lifelong expensive enzyme replacement therapy, while providing both metabolic detoxification and immune recovery.
Solution Approach 2:
The genetically modified patient's own stem cells serve themselves by continuously producing ADA enzyme endogenously. This self-service mechanism replaces the need for external enzyme replacement therapy, achieving both metabolic detoxification and immune recovery while eliminating the burden of lifelong expensive treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The EFS promoter-driven lentiviral vectors demonstrate effective and sustained ADA gene expression, leading to significant immune recovery and metabolic detoxification in patients, with reduced risks of adverse effects compared to previous vector systems.
Implementation Method 1
the EFS short form of the elongation factor alpha promoter (EFS)... the promoter drives expression of the transgene in lymphoid and myeloid cells
Implementation Method 2
self-inactivating HIV-1 lentiviral vectors for the treatment of ADA-SCID... following correction of haematopoietic stem cells (HSCs)
Implementation Method 3
The enzyme (ADA) catalyses the deamination of deoxyadenosine and adenosine to deoxyinosine and inosine respectively
Data Source
Figure 1a~1b
Figure 2a~2e
Figure 3a~3c
AI summary
The present invention relates to the prevention and/or treatment of ADA-SCID, in a patient.